Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085956 · ClinicalTrials.gov registry record · Phase 3
Effects of Arzoxifene on Bone Mass and the Uterus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00085956 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants.
The verdict
NCT00085956, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: * The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. * The effects of arzoxifene on the uterus (womb) in postmenopausal women. * The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. * The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. * The safety of arzoxifene and any side effects that might be associated with its use.
Interventions
- DRUG Placebo
- DRUG Arzoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085956
The ClinicalTrials.gov registry entry for NCT00085956 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00085956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085956 about?
NCT00085956 is a clinical study titled "Effects of Arzoxifene on Bone Mass and the Uterus". The purposes of this study are to determine: * The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. * The effects of arzoxifene on the uterus (womb) in postmenopausal women. * The effects of arzoxifene on blood tests that measure changes in bon...
What is the current status of trial NCT00085956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-04. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00085956?
The interventions under investigation include: Placebo (DRUG), Arzoxifene (DRUG).
Who is sponsoring clinical trial NCT00085956?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.